UPDATE 1-Biogen profit beats on higher Tecfidera sales

April 21 (Reuters) - Biogen Inc reported a better-than-expected first-quarter profit helped by higher demand for its key multiple sclerosis (MS) drug, Tecfidera.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.